Compositions and methods for diagnosing and assessing rheumatoid arthritis
AssigneeInova Diagnostics, Inc.
InventorMichael Mahler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of anti-PAD IgA as a clinical biomarker for diagnostic and prognostic information in rheumatoid arthritis (RA) patients. The disclosure further provides methods and compositions for the detection anti-PAD IgA in a biological sample.
Claims32
A method of diagnosing rheumatoid arthritis (RA), comprising:
- (a) contacting a biological sample from a subject suspected of having RA with a peptidyl arginine deiminase (PAD) or an antigenic fragment thereof, and
- (b) detecting the presence of an anti-PAD IgA in said biological sample, wherein the presence of said anti-PAD IgA is indicative of RA.
A method of assessing disease severity in a subject having rheumatoid arthritis (RA), comprising:
- (a) contacting a biological sample from a subject having RA with a peptidyl arginine deiminase (PAD) or an antigenic fragment thereof, and
- (b) detecting the presence of an anti-PAD IgA in said biological sample, wherein the presence of said anti-PAD IgA is indicative of severity of RA.
(canceled)
(canceled)
11-15. (canceled)
(canceled)
(canceled)
22-24. (canceled)
26-30. (canceled)
A detection kit, comprising:
- (a) a peptidyl arginine deiminase (PAD), or antigenic fragment thereof;
- (b) a detection probe specific to anti-PAD IgA, and
- (c) a solid support,
- wherein said kit optionally comprises
- (d) a positive control, wherein the positive control comprises anti-IgA, or one or more ancillary reagents, wherein said one or more ancillary reagents is selected from the group consisting of an incubation buffer, a wash buffer, a detection buffer and a detection instrument.
32-37. (canceled)
39-41. (canceled)
43-45. (canceled)
47-51. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.